Simple jQuery Dropdowns

Browsing by Author International AIDS Vaccine Initiative

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 8 of 8
Issue DateTitleAuthor(s)
17-Jul-2016Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8 + T cells with limited breadth of HIV-1 inhibitionPeter J. Hayes; Josephine H. Cox; Adam R. Coleman; Natalia Fernandez; Philip J. Bergin; Jakub T. Kopycinski; Sorachai Nitayaphan; Punnee Pitisuttihum; Mark De Souza; Ann Duerr; Cecilia Morgan; Jill W. Gilmour; Chelsea and Westminster Hospital; Armed Forces Research Institute of Medical Sciences, Thailand; Mahidol University; SEARCH; Fred Hutchinson Cancer Research Center; International AIDS Vaccine Initiative
1-May-2005Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continentsPaul M. Coplan; Swati B. Gupta; Sheri A. Dubey; Punnee Pitisuttithum; Alex Nikas; Bernard Mbewe; Efthyia Vardas; Mauro Schechter; Esper G. Kallas; Dan C. Freed; Tong Ming Fu; Christopher T. Mast; Pilaipan Puthavathana; James Kublin; Kelly Brown Collins; John Chisi; Richard Pendame; Scott J. Thaler; Glenda Gray; James Mcintyre; Walter L. Straus; Jon H. Condra; Devan V. Mehrotra; Harry A. Guess; Emilio A. Emini; John W. Shiver; Merck Research Laboratories; Mahidol University; Malawi College of Medicine; Ministry of Population and Health; Universidade Federal do Rio de Janeiro; Universidade Federal de Sao Paulo; University of Witwatersrand; Intl. Partnership for Microbicides; The University of North Carolina at Chapel Hill; International AIDS Vaccine Initiative; International Partnership for Microbicides
21-Jul-2018Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)Dan H. Barouch; Frank L. Tomaka; Frank Wegmann; Daniel J. Stieh; Galit Alter; Merlin L. Robb; Nelson L. Michael; Lauren Peter; Joseph P. Nkolola; Erica N. Borducchi; Abishek Chandrashekar; David Jetton; Kathryn E. Stephenson; Wenjun Li; Bette Korber; Georgia D. Tomaras; David C. Montefiori; Glenda Gray; Nicole Frahm; M. Juliana McElrath; Lindsey Baden; Jennifer Johnson; Julia Hutter; Edith Swann; Etienne Karita; Hannah Kibuuka; Juliet Mpendo; Nigel Garrett; Kathy Mngadi; Kundai Chinyenze; Frances Priddy; Erica Lazarus; Fatima Laher; Sorachai Nitayapan; Punnee Pitisuttithum; Stephan Bart; Thomas Campbell; Robert Feldman; Gregg Lucksinger; Caroline Borremans; Katleen Callewaert; Raphaele Roten; Jerald Sadoff; Lorenz Scheppler; Mo Weijtens; Karin Feddes-de Boer; Daniëlle van Manen; Jessica Vreugdenhil; Roland Zahn; Ludo Lavreys; Steven Nijs; Jeroen Tolboom; Jenny Hendriks; Zelda Euler; Maria G. Pau; Hanneke Schuitemaker; Janssen Vaccines & Prevention B.V.; Centre for the AIDS Programme of Research in South Africa; International AIDS Vaccine Initiative; Makerere University; Janssen; Massachusetts Institute of Technology; Miami Research Associates; National Institute of Allergy and Infectious Diseases; Brigham and Women's Hospital; University of Witwatersrand; HJF; Walter Reed Army Institute of Research; Mahidol University; University of Colorado at Denver; Duke University; Los Alamos National Laboratory; Royal Thai Army; Fred Hutchinson Cancer Research Center; Harvard Medical School; University of Massachusetts Medical School; Optimal Research LLC; Tekton Research; Janssen Infectious Diseases; Rwanda Zambia HIV Research Group
1-Feb-2007Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USAJim Ackland; Susan Allen; Daniel Barth-Jones; Deborah Birx; Elwyn Chomba; Gavin Churchyard; Ann Duerr; Shuigao Jin; Margaret Johnston; Patricia E. Fast; Alan Fix; Mary Foulkes; Dean Follmann; Raymond Hutubessy; Siobhan Malone; Ronald Gray; Abhay Indrayan; Jonathan Levin; Bonnie J. Mathieson; Timothy D. Mastro; John McNeil; Saladin Osmanov; Punnee Pitisuttithum; Barry Peters; Etienne Karita; Michael N. Robertson; R. Ramakrishnan; Helen Rees; Wasima Rida; Yuhua Ruan; Eric Sandström; Claudia Schmidt; Peter Smith; Steven Self; Georges Thiry; Judith Wasserheit; Frances Priddy; Ibou Thior; Mitchell Warren; David Cooper; Pontiano Kaleebu; Ruth Macklin; Godfrey Tangwa; Global BioSolutions; Rollins School of Public Health; Wayne State University School of Medicine; Centers for Disease Control and Prevention; Zambia-UAB HIV Research Project; Ernest Oppenheimer Hospital; Scientific Support Unit; Chinese Center for Disease Control and Prevention; National Institute of Allergy and Infectious Diseases; International AIDS Vaccine Initiative; Food and Drug Administration; Organisation Mondiale de la Sante; Bill and Melinda Gates Foundation; Johns Hopkins Bloomberg School of Public Health; University College of Medical Sciences; South African Medical Research Council; OAR HIV/AIDS Vaccine Coordinating Committee; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention; Mahidol University; Guy's and St Thomas' NHS Foundation Trust; Projet San Francisco Rwanda; Merck & Co., Inc.; National Institute of Epidemiology; University of Witwatersrand; Statistics Collaborative; Karolinska University Hospital; London School of Hygiene & Tropical Medicine; Statistical Center for HIV/AIDS Research and Prevention; IAVI; HIV Vaccine Trials Network; Emory University; Botswana Harvard AIDS Institute Partnership; AIDS Vaccine Advocacy Coalition; Kirby Institute; Uganda Virus Research Institute; Albert Einstein College of Medicine of Yeshiva University; Universite de Yaounde I
1-Jul-2009Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithmMelissa D. Simek; Wasima Rida; Frances H. Priddy; Pham Pung; Emily Carrow; Dagna S. Laufer; Jennifer K. Lehrman; Mark Boaz; Tony Tarragona-Fiol; George Miiro; Josephine Birungi; Anton Pozniak; Dale A. McPhee; Olivier Manigart; Etienne Karita; André Inwoley; Walter Jaoko; Jack DeHovitz; Linda Gail Bekker; Punnee Pitisuttithum; Robert Paris; Laura M. Walker; Pascal Poignard; Terri Wrin; Patricia E. Fast; Dennis R. Burton; Wayne C. Koff; International AIDS Vaccine Initiative; Monogram Biosciences; Scripps Research Institute; Emory University; Uganda Virus Research Institute; National Center in HIV-1 Epidemiology and Clinical Research; St Stephen's AIDS Trust; Advanced Bioadjuvants; University of Nairobi; SUNY Downstate Medical Center; University of Cape Town; Mahidol University; Armed Forces Research Institute of Medical Sciences, Thailand; Imperial College London; Sanofi Pasteur
4-Nov-2016Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in childrenKulkanya Chokephaibulkit; Chukiat Sirivichayakul; Usa Thisyakorn; Chitsanu Pancharoen; Mark Boaz; Alain Bouckenooghe; Emmanuel Feroldi; Mahidol University; King Chulalongkorn Memorial Hospital, Faculty of Medicine Chulalongkorn University; Sanofi Pasteur; Medical Affairs & Clinical Sciences Department; Sanofi Pasteur; International AIDS Vaccine Initiative
9-Dec-2010Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia ankara-HIV-1 vaccine candidateJeffrey R. Currier; Viseth Ngauy; Mark S. de Souza; Silvia Ratto-Kim; Josephine H. Cox; Victoria R. Polonis; Patricia Earl; Bernard Moss; Sheila Peel; Bonnie Slike; Somchai Sriplienchan; Prasert Thongcharoen; Robert M. Paris; Merlin L. Robb; Jerome Kim; Nelson L. Michael; Mary A. Marovich; US MIlitary HIV Research Program/Henry M. Jackson Foundation; Armed Forces Research Institute of Medical Sciences, Thailand; International AIDS Vaccine Initiative; National Institute of Allergy and Infectious Diseases; Mahidol University
15-May-2012The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelopeMark S. De Souza; Silvia Ratto-Kim; Weerawan Chuenarom; Alexandra Schuetz; Somsak Chantakulkij; Bessara Nuntapinit; Anais Valencia-Micolta; Doris Thelian; Sorachai Nitayaphan; Punnee Pitisuttithum; Robert M. Paris; Jaranit Kaewkungwal; Nelson L. Michael; Supachai Rerks-Ngarm; Bonnie Mathieson; Mary Marovich; Jeffrey R. Currier; Jerome H. Kim; Supamit Chunsuttiwat; Nakorn Premsri; Chawetsan Namwat; Prayura Kunasol; Prasert Thongcharoen; Chirasak Khamboonruang; Valai Bussaratid; Wirach Maek-a-nantawat; Jittima Dhitavat; Pravan Suntharasamai; Swangjai Pungpak; Siriwan Vanijanonta; Jaranit Kaewkunwal; Amnat Khamsiriwatchara; Pawinee Jarujareet; Chirapa Easmila; Suchana Tabprasit; Viseth Ngauy; Robert Paris; Michael Benenson; Patricia Morgan; Arthur Brown; Mark De Souza; Rapee Trichavaroj; Nusara Thaitawat; Kanyasiri Kongnonkok; Boot Keawboon; Yuwadee Phuang-Ngern; Susan Mason; Sanjay Gurunathan; Jim Tartaglia; John G. McNeil; Robin Harkness; Claude Meric; Lynn Baglyos; Raphaelle El Habib; Don Francis; Carter Lee; Elizabeth Adams; Merlin L. Robb; Mark Milazzo; Amy Bolen; Beryl Wessner; Jeffrey Currier; Deborah L. Birx; Don Stablein; Terry Germanson; Len Dally; Jean Louis Excler; Jeffrey Berenberg; Armed Forces Research Institute of Medical Sciences, Thailand; Walter Reed Army Institute of Research; Mahidol University; Thailand Ministry of Public Health; National Institutes of Health, Bethesda; Sanofi Pasteur; Sanofi Pasteur; Global Solutions in Infectious Diseases; National Institute of Allergy and Infectious Diseases; U.S. Army Medical Research and Materiel Command; Centers for Disease Control and Prevention; The EMMES Corporation; International AIDS Vaccine Initiative; Tripler Regional Med Center